PD‐1 inhibitors (e.g., Nivolumab, Pembrolizumab) were primarily associated with hepatitis and liver function abnormalities, whereas PD‐L1 inhibitors (e.g., Durvalumab, Atezolizumab) were more frequently linked to immune‐mediated liver disease and liver failure. Here, CD274 is linked to liver failure.